Dallas, Texas 12/17/2014 (FINANCIALSTRENDS) – Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) recently provided update on its Phase Ib ovarian cancer study. The company noted that total eighteen patients have been dosed with Tetralogic’s birinapant in combination with Amgen, Inc. (NASDAQ:AMGN)’s conatumumab.
Preliminary results suggest a pharmaco-dynamic interaction between the two drugs, resulting in adverse events at lower than expected dose levels. So far partial response is observed in one patient, stable disease in two patients and scans are awaited for three patients.
Study Details and Future Plans
Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) is conducting Phase Ib study in patients with ovarian cancer, who might have failed up to three rounds of chemotherapy. The trial involves twice weekly administration of birinapant (3 weeks out of 4 / 4 weeks out of 4) in combination with conatumumab dosed every 2 weeks. conatumumab is TRAIL-receptor-2 agonist anti-body. Patients are scanned for assessment after every 8 weeks.
Following the preliminary review of the initial findings, the company announced that it would progress with the expansion phase of the study. However, it would reduce the dose of birinapant while limiting dosing to 3 weeks out of 4. The company would continue the trial to enroll at least 30 patients.
Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) is advancing its lead candidate birinapant which is under various Phase I/II trials. The company is testing its efficacy for possible treatment of Myelodysplastic Syndromes, Colorectal Cancer and Ovarian Cancer. In November, the company announced additional findings from birinapant related preclinical studies, which assessed its ability in Hepatitis B Virus mouse models.
In addition, the company is developing another candidate suberohydroxamic acid (4-methoxycarbonyl) phenyl ester or SHAPE, which is in Phase I trial involving patients with Cutaneous T-Cell Lymphoma.
On Tuesday, the stock fell 23.76% in response to unpromising Phase I results of ovarian cancer study. The stock is trading much below its 52-week high of $14.75.